Article Details

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in ...

Retrieved on: 2025-04-15 20:25:54

Tags for this article:

Click the tags to see associated articles and topics

First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in .... View article details on hiswai:

Excerpt

In 2014, the first anti- programmed death-1 (PD-1) monoclonal antibody was approved by the FDA for the treatment of melanoma, marking a significant ...

Article found on: www.nature.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo